Ms Solomon currently serves as Venture Chair at Redesign Health, a company that builds and funds transformative healthcare businesses. Prior to that role, she was Chief Innovation Officer at Dana-Farber Cancer Institute (DFCI) where she led a team focused on commercializing DFCI’s science and technology, working with industry, academic and investment partners to accelerate the pace of getting that work to patients. She previously served as the founding executive director of Brigham and Women’s Innovation Hub and was the director of Strategy and Innovation in the Brigham Research Institute. She is also the co-founder and board member of the Food Allergy Science Initiative (FASI), which works to bring research and science together to deliver breakthroughs in treatment and transform the lives of patients. As co-founder, she has helped grow FASI into a $30 million effort that recently spun out of the Broad Institute of MIT and Harvard. In addition, Ms Solomon serves on the board of directors of Anomaly. Ms Solomon received her Master of Business Administration (MBA) from Harvard Business School and her Bachelor of Arts (BA) in English from Cornell University.